Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBD

References

• Shi Y, Wu Y, Zhang W, et al. Enabling the ‘host jump’: structural determinants of receptor-binding specificity in influenza A viruses. Nat Rev Microbiol. 2014 Dec;12(12):822–31. doi:10.1038/nrmicro3362
   PubMed Web of Science ®Google Scholar
• Smith GJ, Vijaykrishna D, Bahl J, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature. 2009;459(7250):1122–1125. doi:10.1038/nature08182
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi:10.1056/NEJMoa2001017
   PubMed Web of Science ®Google Scholar
• Gao GF. From “A”IV to “Z”IKV: attacks from emerging and Re-emerging pathogens. Cell. 2018;172(6):1157–1159. doi:10.1016/j.cell.2018.02.025
   PubMed Web of Science ®Google Scholar
• Wu Y, Wu Y, Tefsen B, et al. Bat-derived influenza-like viruses H17N10 and H18N11. Trends Microbiol. 2014 Apr;22(4):183–191. doi:10.1016/j.tim.2014.01.010
   PubMed Web of Science ®Google Scholar
• Liu WJ, Wu Y, Bi YH, et al. Emerging HxNy influenza A viruses. Cold Spring Harb Perspect Med. 2022 Feb;12(2):a038406. doi:10.1101/cshperspect
   PubMed Web of Science ®Google Scholar
• Zhang F, Bi Y, Wang J, et al. Human infections with recently-emerging highly pathogenic H7N9 avian influenza virus in China. J Infect. 2017;75(1):71–75. doi:10.1016/j.jinf.2017.04.001
   PubMed Web of Science ®Google Scholar
• Tong XC, Weng SS, Xue F, et al. First human infection by a novel avian influenza A(H7N4) virus. J Infect. 2018 Sep;77(3):249–257. doi:10.1016/j.jinf.2018.06.002
   PubMed Web of Science ®Google Scholar
• de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12(10):1203–1207. doi:10.1038/nm1477
   PubMed Web of Science ®Google Scholar
• Bi Y, Tan S, Yang Y, et al. Clinical and immunological characteristics of human infections with H5N6 avian influenza virus. Clin Infect Dis. 2019;68(7):1100–1109. doi:10.1093/cid/ciy681
   PubMed Web of Science ®Google Scholar
• Pyankova OG, Susloparov IM, Moiseeva AA, et al. Isolation of clade 2.3.4.4b A(H5N8), a highly pathogenic avian influenza virus, from a worker during an outbreak on a poultry farm, Russia, December 2020. Euro Surveill. 2021 Jun;26(24):1560–7917. doi:10.2807/1560-7917.ES.2021.26.24.2100439
   PubMedGoogle Scholar
• Wang Y, Niu S, Zhang B, et al. The whole genome analysis for the first human infection with H10N3 influenza virus in China. J Infect 2021 Jun 27;S0163-4453(21)00318-2. doi:10.1016/j.jinf.2021.06.021
   Google Scholar
• Yang R, Sun H, Gao F, et al. Human infection of avian influenza A H3N8 virus and the viral origins: a descriptive study. Lancet Microbe. 2022;3(11):e824–e834. doi:10.1016/S2666-5247(22)00192-6
   PubMedGoogle Scholar
• Uyeki TM, Hui DS, Zambon M, et al. Influenza. Lancet. 2022;400(10353):693–706. doi:10.1016/S0140-6736(22)00982-5
   PubMed Web of Science ®Google Scholar
• Sayers DR. Severe acute respiratory syndrome coronavirus 2 vaccine boosters: An influenza vaccine perspective. Mil Med. 2022 Aug 9;usac243. doi:10.1093/milmed/usac243
   PubMed Web of Science ®Google Scholar
• Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021;21(2):73–82. doi:10.1038/s41577-020-00480-0
   PubMed Web of Science ®Google Scholar
• Gao GF. Science-based COVID-19 vaccine development. Natl Sci Rev. 2021;8(10):nwab193, doi:10.1093/nsr/nwab193
   PubMed Web of Science ®Google Scholar
• Zhao X, Li D, Ruan W, et al. Effects of a prolonged booster interval on neutralization of Omicron variant. N Engl J Med. 2022;386(9):894–896. doi:10.1056/NEJMc2119426
   PubMed Web of Science ®Google Scholar
• Zhao X, Zhang R, Qiao S, et al. Omicron SARS-CoV-2 neutralization from inactivated and ZF2001 vaccines. N Engl J Med. 2022;387(3):277–280. doi:10.1056/NEJMc2206900
   PubMed Web of Science ®Google Scholar
• Qu L, Yi Z, Shen Y, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell. 2022;185(10):1728–1744.e16. doi:10.1016/j.cell.2022.03.044
   PubMed Web of Science ®Google Scholar
• Xu R, Ekiert DC, Krause JC, et al. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science. 2010 Apr 16;328(5976):357–360. doi:10.1126/science.1186430
   PubMed Web of Science ®Google Scholar
• Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem. 2000;69:531–569. doi:10.1146/annurev.biochem.69.1.531
   PubMed Web of Science ®Google Scholar
• Impagliazzo A, Milder F, Kuipers H, et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science. 2015;349(6254):1301–1306. doi:10.1126/science.aac7263
   PubMed Web of Science ®Google Scholar
• Yassine HM, Boyington JC, McTamney PM, et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med. 2015;21(9):1065–1070. doi:10.1038/nm.3927
   PubMed Web of Science ®Google Scholar
• Dreyfus C, Laursen NS, Kwaks T, et al. Highly conserved protective epitopes on influenza B viruses. Science (New York, NY). 2012 Sep 14;337(6100):1343–1348. doi:10.1126/science.1222908
   Google Scholar
• Shi R, Shan C, Duan X, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584(7819):120–124. doi:10.1038/s41586-020-2381-y
   PubMed Web of Science ®Google Scholar
• Zheng SQ, Palovcak E, Armache JP, et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat Methods. 2017 Apr;14(4):331–332. doi:10.1038/nmeth.4193
   PubMed Web of Science ®Google Scholar
• Rohou A, Grigorieff N. CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J Struct Biol. 2015;192(2):216–221. doi:10.1016/j.jsb.2015.08.008
   PubMed Web of Science ®Google Scholar
• Zivanov J, Nakane T, Forsberg BO, et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife. 2018 Nov 9;7:e42166. doi:10.7554/eLife.42166
   PubMed Web of Science ®Google Scholar
• Punjani A, Rubinstein JL, Fleet DJ, et al. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods. 2017;14(3):290–296. doi:10.1038/nmeth.4169
   PubMed Web of Science ®Google Scholar
• Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera? A visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–1612. doi:10.1002/jcc.20084
   PubMed Web of Science ®Google Scholar
• Sui J, Hwang WC, Perez S, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol. 2009 Mar;16(3):265–273. doi:10.1038/nsmb.1566
   PubMed Web of Science ®Google Scholar
• Boyoglu-Barnum S, Hutchinson GB, Boyington JC, et al. Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses. Nat Commun. 2020;11(1):791. doi:10.1038/s41467-020-14579-4
   PubMed Web of Science ®Google Scholar
• Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection protects against rechallenge in rhesusmacaques. Science. 2020;369(6505):812–817. doi:10.1126/science.abc4776
   PubMed Web of Science ®Google Scholar
• Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465–469. doi:10.1038/s41586-020-2196-x
   PubMed Web of Science ®Google Scholar
• Domachowske J, Madhi SA, Simoes EAF, et al. Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity. N Engl J Med. 2022;386(9):892–894. doi:10.1056/NEJMc2112186
   PubMed Web of Science ®Google Scholar
• Xu K, Gao P, Liu S, et al. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell. 2022;185(13):2265–2278.e14. doi:10.1016/j.cell.2022.04.029
   PubMed Web of Science ®Google Scholar
• Domnich A, Orsi A, Trombetta CS, et al. COVID-19 and seasonal influenza vaccination: cross-protection, Co-administration, combination vaccines, and hesitancy. Pharmaceuticals (Basel, Switzerland). 2022 Mar 8;15(3):322. doi:10.3390/ph15030322
   PubMedGoogle Scholar
• Koff WC, Berkley SF. A universal coronavirus vaccine. Science. 2021;371(6531):759. doi:10.1126/science.abh0447
   PubMed Web of Science ®Google Scholar
• Martinez DR, Schafer A, Leist SR, et al. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science. 2021;373(6558):991–998. doi:10.1126/science.abi4506
   PubMed Web of Science ®Google Scholar
• Cao K, Wang X, Peng H, et al. A single vaccine protects against SARS-CoV-2 and influenza virus in mice. J Virol 2022 Feb 23;96(4):e0157821. doi:10.1128/jvi.01578-21
   PubMed Web of Science ®Google Scholar
• Throsby M, van den Brink E, Jongeneelen M, et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PloS one. 2008;3(12):e3942. doi:10.1371/journal.pone.0003942
   PubMed Web of Science ®Google Scholar
• Ekiert DC, Bhabha G, Elsliger MA, et al. Antibody recognition of a highly conserved influenza virus epitope. Science. 2009 Apr 10;324(5924):246–251. doi:10.1126/science.1171491
   PubMed Web of Science ®Google Scholar
• Corti D, Voss J, Gamblin SJ, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333(6044):850–856. doi:10.1126/science.1205669
   PubMed Web of Science ®Google Scholar
• Hai R, Krammer F, Tan GS, et al. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J Virol. 2012;86(10):5774–5781. doi:10.1128/JVI.00137-12
   PubMed Web of Science ®Google Scholar
• Dreyfus C, Ekiert DC, Wilson IA. Structure of a classical broadly neutralizing stem antibody in complex with a pandemic H2 influenza virus hemagglutinin. J Virol. 2013;87(12):7149–7154. doi:10.1128/JVI.02975-12
   PubMed Web of Science ®Google Scholar
• Steel J, Lowen AC, Wang TT, et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio. 2010 May 18;1(1):e00018–10. doi:10.1128/mBio.00018-10
   PubMed Web of Science ®Google Scholar
• Zhu F, Zhuang C, Chu K, et al. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. The Lancet Respiratory Medicine. 2022;10(8):749–760. doi:10.1016/S2213-2600(22)00131-X
   PubMed Web of Science ®Google Scholar
• Chen J, Wang P, Yuan L, et al. A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Science Bulletin. 2022;67(13):1372–1387. doi:10.1016/j.scib.2022.05.018
   PubMed Web of Science ®Google Scholar
• Chaparian RR, Harding AT, Hamele CE, et al. A virion-based combination vaccine protects against influenza and SARS-CoV-2 disease in mice. J Virol 2022 Aug 10;96(15):e0068922. doi:10.1128/jvi.00689-22
   PubMed Web of Science ®Google Scholar
• Wu NC, Wilson IA. Structural insights into the design of novel anti-influenza therapies. Nat Struct Mol Biol. 2018 Feb;25(2):115–121. doi:10.1038/s41594-018-0025-9
   PubMed Web of Science ®Google Scholar
• Joyce MG, Wheatley AK, Thomas PV, et al. Vaccine-induced antibodies that neutralize group 1 and group 2 influenza A viruses. Cell. 2016;166(3):609–623. doi:10.1016/j.cell.2016.06.043
   PubMed Web of Science ®Google Scholar
• Corti D, Voss J, Gamblin SJ, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333(6044):850–856. doi:10.1126/science.1205669
   PubMed Web of Science ®Google Scholar
• Dreyfus C, Laursen NS, Kwaks T, et al. Highly conserved protective epitopes on influenza B viruses. Science. 2012;337(6100):1343–1348. doi:10.1126/science.1222908
   PubMed Web of Science ®Google Scholar
• Biswas A, Chakrabarti AK, Dutta S. Current challenges: from the path of “original antigenic sin” towards the development of universal flu vaccines. Int Rev Immunol. 2020;39(1):21–36. doi:10.1080/08830185.2019.1685990
   PubMed Web of Science ®Google Scholar
• van der Lubbe JEM, Verspuij JWA, Huizingh J, et al. Mini-HA is superior to full length hemagglutinin immunization in inducing stem-specific antibodies and protection against group 1 influenza virus challenges in mice. Front Immunol. 2018;9:2350. doi:10.3389/fimmu.2018.02350
   PubMed Web of Science ®Google Scholar
• Eggink D, Goff PH, Palese P. Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain. J Virol 2014;88(1):699–704. doi:10.1128/JVI.02608-13
   PubMed Web of Science ®Google Scholar
• Krammer F, Pica N, Hai R, et al. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 2013;87(12):6542–6550. doi:10.1128/JVI.00641-13
   PubMed Web of Science ®Google Scholar
• Nachbagauer R, Feser J, Naficy A, et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat Med. 2021;27(1):106–114. doi:10.1038/s41591-020-1118-7
   PubMed Web of Science ®Google Scholar
• Liu WC, Nachbagauer R, Stadlbauer D, et al. Sequential immunization with live-attenuated chimeric hemagglutinin-based vaccines confers heterosubtypic immunity against influenza A viruses in a preclinical ferret model. Front Immunol. 2019;10:756. doi:10.3389/fimmu.2019.00756
   PubMed Web of Science ®Google Scholar
• Liu WC, Nachbagauer R, Stadlbauer D, et al. Chimeric hemagglutinin-based live-attenuated vaccines confer durable protective immunity against Influenza A viruses in a preclinical ferret model. Vaccines (Basel). 2021 Jan 11;9(1):40. doi:10.3390/vaccines9010040
   Web of Science ®Google Scholar
• Broecker F, Liu STH, Suntronwong N, et al. A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains. NPJ Vaccines. 2019;4:31. doi:10.1038/s41541-019-0126-4
   PubMed Web of Science ®Google Scholar
• Sun S, Cai Y, Song TZ, et al. Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. Cell Res. 2021;31(9):1011–1023. doi:10.1038/s41422-021-00531-8
   PubMed Web of Science ®Google Scholar
• Dai L, Zheng T, Xu K, et al. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. Cell. 2020;182(3):722–733.e11. doi:10.1016/j.cell.2020.06.035
   PubMed Web of Science ®Google Scholar
• He C, Yang J, Hong W, et al. A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant. Nat Commun. 2022;13(1):5459. doi:10.1038/s41467-022-33209-9
   PubMed Web of Science ®Google Scholar
• Wang W, Huang B, Zhu Y, et al. Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice. Cell Mol Immunol. 2021;18(3):749–751. doi:10.1038/s41423-021-00643-6
   PubMed Web of Science ®Google Scholar
• Andrews SF, Cominsky LY, Shimberg GD, et al. An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans. Sci Transl Med. 2023;15(692):eade4976. doi:10.1126/scitranslmed.ade4976
   PubMed Web of Science ®Google Scholar
• Widge AT, Hofstetter AR, Houser KV, et al. An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults. Sci Transl Med. 2023;15(692):eade4790. doi:10.1126/scitranslmed.ade4790
   PubMed Web of Science ®Google Scholar